Grogan Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The Grogan staging system stratifies ATTR‑CM prognosis using NT‑proBNP and troponin thresholds to classify disease severity.
NT-proBNP
≤ 3000 pg/mL0> 3000 pg/mL+1
Troponin T
≤ 0.05 ng/mL0> 0.05 ng/mL+1
使用適応
Used to stage confirmed ATTR‑CM at diagnosis by NT‑proBNP (>3000 ng/L) and eGFR (<45 mL/min) to stratify prognosis (Stage I–III) and guide timing of disease‑modifying therapy and referral decisions 1 [Level II evidence]. Provides median survival discrimination (≈69 vs 47 vs 24 months across stages) and helps identify patients most likely to benefit from early tafamidis or acoramidis initiation 2 [Level II evidence].
洞察と注意事項
Uses troponin T and NT-proBNP to stratify mortality risk (higher levels predict markedly worse survival) 1 [Level II evidence].
- Prognosis is stage‑dependent but underestimates survival in the tafamidis era, as staging was derived pre‑therapy.
- Kidney function and clinical HF severity add independent prognostic value and may up‑ or down‑stage risk 2 [Level III evidence].
- Should guide counseling, not treatment eligibility alone.